Renal Cancer - Results from #360

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study). May 7, 2024

Clinical Implications of a Six-Protein Signature in Bone Metastasis of Renal Cell Carcinoma. May 7, 2024

High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. May 6, 2024

Development and validation of a multicenter Cox regression model to predict all-cause mortality in patients with renal masses suspicious for renal cancer. May 6, 2024

Disparities in Trend of Renal Cell Carcinoma Mortality in the United States. May 6, 2024

Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region. May 6, 2024

Geographic variation of mutagenic exposures in kidney cancer genomes. May 3, 2024

Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial. May 3, 2024

Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal. May 2, 2024

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. May 2, 2024

Comparing Perioperative Complications of Off-Clamp versus On-Clamp Partial Nephrectomy for Renal Cancer Using a Novel Energy Balancing Weights Method. May 1, 2024

Molecular subtypes as potential biomarkers in renal cell carcinoma. May 1, 2024

Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. April 30, 2024

Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus. April 30, 2024

Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii. April 30, 2024

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). April 30, 2024

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. April 29, 2024

Network analysis of histopathological image features and genomics data improving prognosis performance in clear cell renal cell carcinoma. April 29, 2024

A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma. April 26, 2024

First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. April 26, 2024

Page 19 of 455